Global Locations

Bosutinib



Chemical Properties of 'Bosutinib'

CAT No. :

CS-T-07791
CAS Registry No. : 380843-75-4
Category : API Standards
Molecular Weight: 530.45
Molecular Formula : C₂₆H₂₉Cl₂N₅O₃



OTHER INFORMATION of 'Bosutinib'
Therapeutic : Anti-Cancer / Oncology
Therapeutic : Anti-Cancer / Oncology
IUPAC Name :4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile
Applicationnotes :"A novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. "
Synonym :Not available
References :"Bjorge, J,, et al,: J, Biol, Chem,, 275, 41439"
Smileys :ClC1=CC(Cl)=C(OC)C=C1NC(C2=C3C=C(OCCCN4CCN(C)CC4)C(OC)=C2)=C(C=N3)C#N
Use Classification :Human drugs -> Bosulif -> EMA Drug Category
EC Number :700-455-1
UNII :5018V4AEZ0
NCI Thesaurus Code :C60809
RXCUI :1307619
MeSH Entry Terms :bosutinib
Other Synonyms :Bosutinib
Removed Synonyms :bosutinib hydrate
Metabolite Pathways :Bosutinib Inhibition of BCR-ABL
Toxicity Summary :Most common adverse reactions (incidence greater than 20%) are diarrhea, nausea, thrombocytopenia, vomiting, abdominal pain, rash, anemia, pyrexia, and fatigue. Because bosutinib is not an inhibitor of c-KIT or PDGF receptor, it has less hematologic toxicities.
Hepatotoxicity :In large clinical trials of bosutinib, elevations in serum aminotransferase levels were common, occurring in up to 58% of bosutinib treated patients. Values greater than 5 times the upper limit of normal (ULN) occurred in 4% to 19% of bosutinib recipients (and 3% of imatinib treated subjects). These abnormalities were usually asymptomatic, but led to discontinuation of therapy in up to 2% of treated patients. In addition, there have been isolated reports of clinically apparent liver injury attributed to bosutinib therapy, although the frequency of this outcome and the clinical features of the injury have not been well defined. The time to onset has generally been within 3 months and the pattern of serum enzyme elevations was usually hepatocellular.
Protein Binding :94% bound to human plasma proteins in vitro. 96% bound to human plasma proteins in healthy subjects ex vivo. Extent of protein binding is not concentration-dependent.
Exact Mass :529.1647452
InChI :InChI=1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31)
InchIKey :UBPYILGKFZZVDX-UHFFFAOYSA-N
Canonical SMILES :CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC
Isomeric SMILES :CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC
Product Description :Bosutinib is an aminoquinoline that is 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline bearing additional cyano and methoxy substituents at positions 3 and 6 respectively. It has a role as an antineoplastic agent and a tyrosine kinase inhibitor. It is a nitrile, a N-methylpiperazine, an aromatic ether, a tertiary amino compound, an aminoquinoline and a dichlorobenzene.
Custom Duty : Applicable
Port of Loading : Canada
Expected Dispatch : 15-Aug-2022
Taxes : Not Applicable
Refund Policy : 30-days money back
Custom Duty : Applicable
Port of Loading : Canada
Expected Dispatch : 15-Aug-2022
Taxes : Not Applicable
Refund Policy : 30-days money back


Looking for a discounted price or need more info for 'Bosutinib (CS-T-07791)' ?

If you are looking for Bulk purchase, Discounted Price, etc. please share your email and the exact quantity you are looking for, our team will respond to you within 30 mins with all the required information.

Looking for a discounted price or need more info for 'Bosutinib (CS-T-07791)' ?

If you are looking for Bulk purchase, Discounted Price, etc. please share your email and the exact quantity you are looking for, our team will respond to you within 30 mins with all the required information.